Search Results

CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.

• Authors : Dou ZJ; Department of the Second Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.; Gao XL

Subjects: Bone Diseases, Metabolic/Bone Diseases, Metabolic/Bone Diseases, Metabolic/*physiopathology ; Cannabinoid Receptor Antagonists/Cannabinoid Receptor Antagonists/Cannabinoid Receptor Antagonists/*administration & dosage ; Hypoxia/Hypoxia/Hypoxia/*physiopathology

• Source: Sleep & breathing = Schlaf & Atmung [Sleep Breath] 2020 Dec; Vol. 24 (4), pp. 1441-1449. Date of Electronic Publication: 2020 Jan 02.Publisher: Springer Country of Publication: Germany NLM ID: 9804161 Publication Model: Print-Electronic Cited Medium:

Record details

The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling.

• Authors : Ruz-Maldonado I; Department of Diabetes, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, SE1 1UL, UK. .; Liu B

Subjects: Cannabinoids/Cannabinoids/Cannabinoids/*metabolism ; Islets of Langerhans/Islets of Langerhans/Islets of Langerhans/*drug effects ; Piperidines/Piperidines/Piperidines/*pharmacology

• Source: Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2020 Nov; Vol. 77 (22), pp. 4709-4723. Date of Electronic Publication: 2020 Jan 10.Publisher: Springer Country of Publication: Switzerland NLM ID: 9705402 Publication Model: Print-Electronic Cited Medium:

Record details

9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity.

• Authors : Chetia, Swapnali; Borah, Gaurab

• Source: Natural Products and Bioprospecting. October, 2020, Vol. 10 Issue 5, p285, 12 p.

Record details

Eriocalyxin B Inhibits Adipogenesis in 3T3-L1 Adipocytes by Cell Cycle Arrest.

• Authors : Mu, Rong-Fang; Niu, Yan-Fen; Wang, Qian

• Source: Natural Products and Bioprospecting. June, 2020, Vol. 10 Issue 3, p131, 10 p.

Record details

[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].

Subjects: Anti-Obesity Agents*/Anti-Obesity Agents*/Anti-Obesity Agents*/adverse effects ; Anti-Obesity Agents*/Anti-Obesity Agents*/Anti-Obesity Agents*/pharmacology ; Anti-Obesity Agents*/Anti-Obesity Agents*/Anti-Obesity Agents*/therapeutic use

• Source: MMW Fortschritte der Medizin [MMW Fortschr Med] 2007 Jun 28; Vol. 149 (27-28), pp. 8.Publisher: Springer Country of Publication: Germany NLM ID: 100893959 Publication Model: Print Cited Medium: Print

Record details

Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis.

• Authors : Cichero E; Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Genova, Italy.; Menozzi G

Subjects: Piperidines/Piperidines/Piperidines/*chemistry ; Pyrazoles/Pyrazoles/Pyrazoles/*chemistry ; Receptor, Cannabinoid, CB1/Receptor, Cannabinoid, CB1/Receptor, Cannabinoid, CB1/*antagonists & inhibitors

• Source: Journal of molecular modeling [J Mol Model] 2008 Dec; Vol. 14 (12), pp. 1131-45. Date of Electronic Publication: 2008 Aug 12.Publisher: Springer Country of Publication: Germany NLM ID: 9806569 Publication Model: Print-Electronic Cited Medium:

Record details

Rimonabant: new data and emerging experience.

• Authors : Wright SM; Comprehensive Weight Control Program, New York-Presbyterian Hospital, Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10065, USA. ; Dikkers C

Subjects: Cannabinoid Receptor Antagonists*; Obesity/Obesity/Obesity/*drug therapy ; Obesity/Obesity/Obesity/*physiopathology

• Source: Current atherosclerosis reports [Curr Atheroscler Rep] 2008 Feb; Vol. 10 (1), pp. 71-8.Publisher: Springer Country of Publication: United States NLM ID: 100897685 Publication Model: Print Cited Medium:

Record details

Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

• Authors : Dibble CT; Beth Israel Deaconess Medical Center, Boston, MA, USA.; Gelfand EV

Subjects: Endocannabinoids*; Cannabinoid Receptor Modulators/Cannabinoid Receptor Modulators/Cannabinoid Receptor Modulators/*therapeutic use ; Lipid Metabolism/Lipid Metabolism/Lipid Metabolism/*drug effects

• Source: Current atherosclerosis reports [Curr Atheroscler Rep] 2007 Nov; Vol. 9 (5), pp. 359-66.Publisher: Springer Country of Publication: United States NLM ID: 100897685 Publication Model: Print Cited Medium: Print

Record details

Selective Action of N-Arachidonoyl Dopamine on Viability and Proliferation of Stromal Cells from Eutopic and Ectopic Endometrium.

• Authors : Ashba AM; V. I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia.; M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Subjects: Cell Proliferation/Cell Proliferation/Cell Proliferation/*drug effects ; Cell Survival/Cell Survival/Cell Survival/*drug effects ; Dopamine/Dopamine/Dopamine/*metabolism

• Source: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2019 May; Vol. 167 (1), pp. 43-46. Date of Electronic Publication: 2019 Jun 08.Publisher: Springer Country of Publication: United States NLM ID: 0372557 Publication Model: Print-Electronic Cited Medium:

Record details

Rimonabant for overweight and "metabolic syndrome": the attempt to supersize disease and risk by pharmaceutical marketing.

• Authors : Banzi R; Italian Cochrane Centre, Mario Negri Institute for Pharmacological Research, Via Eritrea 62, 20157 Milan, Italy.; Moja L

• Source: Internal and emergency medicine [Intern Emerg Med] 2008 Mar; Vol. 3 (1), pp. 53-6. Date of Electronic Publication: 2008 Mar 04.Publisher: Springer Country of Publication: Italy NLM ID: 101263418 Publication Model: Print-Electronic Cited Medium:

Record details